Andrew Philip O'Leary

Andrew Philip O'Leary has a diverse and extensive work experience in the field of scientific research and development. Their most recent role is as a Senior Analytical Development Scientist at Resolution Therapeutics. Prior to that, they worked as an Analytical Development Scientist II at Takeda.

From 2018 to 2022, O'Leary served as an Analytical Development Scientist I at GammaDelta Therapeutics. Before that, they were a Research Scientist II at NOVINTUM BIOSCIENCE LTD, where they were involved in drug discovery and the characterization of specific cancer cells.

O'Leary also worked as a Senior Scientist at GlaxoSmithKline Pharma GmbH from 2016 to 2017. Prior to that, they were a Research Associate at Magnus Life Science, where they focused on developing small-molecule inhibitors to target cancer.

In their earlier career, O'Leary held positions as a Research Associate at the University of Sheffield and as a PhD student at the University of Leicester. At both institutions, they conducted research on various aspects of cell function and angiogenesis.

O'Leary began their career as a Research Assistant at the Biomedical Research Centre, where their work centered around breast cancer biomarker proteins and rat brain membrane proteome. Prior to their scientific career, they worked as a Till Operative at Primark Stores Ltd, gaining experience in stock control and customer service.

Andrew Philip O'Leary obtained their education from two different institutions. From 2004 to 2008, they attended Sheffield Hallam University, where they earned their Bachelor of Science (BSc) degree in Cellular and Molecular Bioscience. Following this, they pursued further studies at the University of Leicester from 2008 to 2012, where they completed their Doctor of Philosophy (Ph.D.) degree in Cell Biology and Dermatology.